Clinical trial NCT00163098: A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD
Official title: A Multi-Centre, Multinational, Randomized, Double-Blind, Placebo Controlled, Proof Of Concept Trial To Assess The Effects Of A Subject-Optimized Dose Of UK-369,003 On Exercise Capacity In Subjects With Chronic Obstructive Pulmonary Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Pulmonary Disease, Chronic Obstructive
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2005-09-13
Enrollment: 136
Sex: ALL
Minimum age (years): 35
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A randomised, controlled study investigating the effect of UK-369,003 on exercise tolerance in patients with COPD


Eligibility criteria: Inclusion Criteria:

* GOLD criteria 2 to 4
* 10 pack year history of smoking

Exclusion Criteria:

* Women of child bearing potential

Primary outcomes:
measure: Effect on exercise tolerance
Secondary outcomes:
measure: Effect on lung function and quality of life
Other outcomes:
Locations:
city: Ciudad de Cordoba
country: Argentina
facility: Pfizer Investigational Site
state: Cordoba
city: San Miguel de Tucuman
country: Argentina
facility: Pfizer Investigational Site
state: Pcia de Tucuman
city: San Miguel de Tucuman
country: Argentina
facility: Pfizer Investigational Site
state: Pcia de Tucuman
city: Rosario
country: Argentina
facility: Pfizer Investigational Site
state: Santa FÃ©
city: Buenos Aires
country: Argentina
facility: Pfizer Investigational Site
city: Buenos Aires
country: Argentina
facility: Pfizer Investigational Site
city: Ciudad de Beurnos Aires
country: Argentina
facility: Pfizer Investigational Site
city: Ciudad de Buenos Aires,
country: Argentina
facility: Pfizer Investigational Site
city: Ciudad de Buenos Aires
country: Argentina
facility: Pfizer Investigational Site
city: Ciudad de Buenos Aires
country: Argentina
facility: Pfizer Investigational Site
city: Provincia de Buenos Aires
country: Argentina
facility: Pfizer Investigational Site
city: Camperdown
country: Australia
facility: Pfizer Investigational Site
state: New South Wales
city: Darlinghurst
country: Australia
facility: Pfizer Investigational Site
state: New South Wales
city: Chermside,
country: Australia
facility: Pfizer Investigational Site
state: Queensland
city: Adelaide
country: Australia
facility: Pfizer Investigational Site
state: South Australia
city: Melbourne
country: Australia
facility: Pfizer Investigational Site
state: Victoria
city: Perth
country: Australia
facility: Pfizer Investigational Site
state: Western Australia
city: Giessen
country: Germany
facility: Pfizer Investigational Site
city: Greifestein
country: Germany
facility: Pfizer Investigational Site
city: Cochin
country: India
facility: Pfizer Investigational Site
state: Kerala
city: Mumbai
country: India
facility: Pfizer Investigational Site
state: Maharashtra
city: Pune
country: India
facility: Pfizer Investigational Site
state: Maharashtra
city: Chennai
country: India
facility: Pfizer Investigational Site
state: Tamilnadu
city: Vellore
country: India
facility: Pfizer Investigational Site
state: Tamilnadu
city: Papworth Everard
country: United Kingdom
facility: Pfizer Investigational Site
state: Cambridgeshire
city: Glasgow
country: United Kingdom
facility: Pfizer Investigational Site
city: Newcastle Upon Tyne
country: United Kingdom
facility: Pfizer Investigational Site
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References: